Evidence map›Paper›PMID 33787478›Full record

ReviewExpert reviews in molecular medicine2021

Methylation multiplicity and its clinical values in cancer.

Xiaofeng Dai, Tiejun Ren, Yuxin Zhang, Nan Nan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert reviews in molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaofeng DaiWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu214122, China.ORCID 0000-0002-0006-4042
Tiejun RenThe Affiliated Luoyang Central Hospital of Zhengzhou University, Zhengzhou University, Luoyang, Henan471000, China.
Yuxin ZhangWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu214122, China.
Nan NanWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu214122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methylation at DNA, RNA and protein levels plays critical roles in many cellular processes and is associated with diverse differentiation events, physiological activities and human diseases. To aid in the diagnostic and therapeutic design for cancer treatment utilising methylation, this review provides a boutique yet comprehensive overview on methylation at different levels including the mechanisms, cross-talking and clinical implications with a particular focus on cancers. We conclude that DNA methylation is the sole type of methylation that has been largely translated into clinics and used for, mostly, early diagnosis. Translating the onco-therapeutic and prognostic values of RNA and protein methylations into clinical use deserves intensive efforts. Simultaneous examination of methylations at multiple levels or together with other forms of molecular markers represents an interesting research direction with profound clinical translational potential.

Indexed as

DNA MethylationNeoplasmsHumansProtein Processing, Post-TranslationalCancerDNA methylationearly diagnosisprotein methylationRNA methylation

Identifiers

PMID33787478
PMCPMC8086398

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.